US10647653B2ActiveUtilityPatentIndex 51
Crystal of monovalent cation salt of 3-hydroxyisovaleric acid and process for producing the crystal
Est. expiryNov 19, 2035(~9.4 yrs left)· nominal 20-yr term from priority
C07C 51/43C07C 59/01C30B 7/105C30B 29/58C07B 2200/13
51
PatentIndex Score
0
Cited by
30
References
23
Claims
Abstract
The present invention provides a crystal of a monovalent cation salt of 3-hydroxyisovaleric acid (hereinafter, referred to as HMB), which is excellent in solubility and easy to handle, and a process for producing the crystal. A crystal of a monovalent cation salt of HMB is precipitated in an aqueous HMB solution containing a monovalent cation-containing compound and having a pH of 4.0 to 9.0, and the crystal of a monovalent cation salt of HMB is thereafter collected from the aqueous solution.
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A crystal of a monovalent cation salt of 3-hydroxyisovaleric acid, wherein the monovalent cation salt is a sodium salt having a powder X-ray diffraction with crystal peaks at diffraction angles (2θ) of 8.4±0.2°, 6.6±0.2°, 19.7±0.2°, 13.3±0.2°, and 29.4±0.2°;
the monovalent cation salt is a sodium salt having a powder X-ray diffraction with crystal peaks at diffraction angles (2θ) of 6.7±0.2°, 13.3±0.2°, and 20.0±0.2°;
the monovalent cation salt is a potassium salt having a powder X-ray diffraction with crystal peaks at diffraction angles (2θ) of 9.0±0.2°, 27.1±0.2°, 23.8±0.2°, 16.1±0.2°, and 22.9±0.2°; or
the monovalent cation salt is an ammonium salt having a powder X-ray diffraction with crystal peaks at diffraction angles (2θ) of 19.9±0.2°, 21.1±0.2°, 29.9±0.2°, 17.3±0.2°, and 18.0±0.2°.
2. The crystal according to claim 1 , wherein the monovalent cation salt is a sodium salt having a powder X-ray diffraction with crystal peaks at diffraction angles (2θ) of 8.4±0.2°, 6.6±0.2°, 19.7±0.2°, 13.3±0.2°, and 29.4±0.2°.
3. The crystal according to claim 2 , wherein the crystal further has peaks at diffraction angles (2θ) of 35.1±0.2°, 17.3±0.2°, 24.5±0.2°, 17.8±0.2°, and 29.9±0.2°.
4. The crystal according to claim 3 , wherein the crystal further has peaks at diffraction angles (2θ) of 16.6±0.2°, 23.9±0.2°, 18.8±0.2°, 18.0±0.2°, and 25.3±0.2°.
5. The crystal according to claim 1 , wherein the monovalent cation salt is a sodium salt having a powder X-ray diffraction with crystal peaks at diffraction angles (2θ) of 6.7±0.2°, 13.3±0.2°, and 20.0±0.2°.
6. The crystal according to claim 5 , wherein the crystal further has peaks at diffraction angles (2θ) of 6.0±0.2°, 47.7±0.2°, 40.6±0.2°, 26.7±0.2°, and 12.0±0.2°.
7. The crystal according to claim 5 , wherein the crystal has approximately the following unit cell parameters when measured at about −180° C.: a=10.6679 Å; b=5.8862 Å; c=26.736 Å; α=90°; β=97.966°; γ=90°; V=1662.6 Å 3 ; and Z=8; the calculated density (D calc , gcm −3 ) is 1.407 gcm −3 ; and the space group is C2/c.
8. The crystal according to claim 1 , wherein the monovalent cation salt is a potassium salt having a powder X-ray diffraction with crystal peaks at diffraction angles (2θ) of 9.0±0.2°, 27.1±0.2°, 23.8±0.2°, 16.1±0.2°, and 22.9±0.2°.
9. The crystal according to claim 8 , wherein the crystal further has peaks at diffraction angles (2θ) of 30.7±0.2°, 8.1±0.2°, 6.4±0.2°, 32.1±0.2°, and 28.5±0.2°.
10. The crystal according to claim 9 , wherein the crystal further has peaks at diffraction angles (2θ) of 40.1±0.2°, 31.1±0.2°, 24.6±0.2°, 18.7±0.2°, and 34.4±0.2°.
11. The crystal according to claim 1 , wherein the monovalent cation salt is an ammonium salt having a powder X-ray diffraction with crystal peaks at diffraction angles (2θ) of 19.9±0.2°, 21.1±0.2°, 29.9±0.2°, 17.3±0.2°, and 18.0±0.2°.
12. The crystal according to claim 11 , wherein the crystal further has peaks at diffraction angles (2θ) of 25.6±0.2°, 8.6±0.2°, 18.2±0.2°, 39.6±0.2°, and 40.5±0.2°.
13. The crystal according to claim 12 , wherein the crystal further has peaks at diffraction angles (2θ) of 28.8±0.2°, 39.7±0.2°, 18.6±0.2°, 15.5±0.2°, and 14.3±0.2°.
14. A process for producing a crystal of a monovalent cation salt of 3-hydroxyisovaleric acid (HMB) of claim 1 , comprising a step of concentrating an aqueous HMB solution containing a monovalent cation-containing compound and having a pH of 4.0 to 10.0 under reduced pressure at 20 to 60° C. to precipitate a crystal of a monovalent cation salt of HMB in the aqueous solution, and a step of collecting the crystal of a monovalent cation salt of HMB from the aqueous solution, wherein the monovalent cation-containing compound is a sodium-containing compound, a potassium-containing compound, or an ammonium-containing compound.
15. A process for producing a crystal of a monovalent cation salt of 3-hydroxyisovaleric acid (HMB) of claim 1 , comprising a step of adding, as a seed crystal, a crystal of a monovalent cation salt of HMB to an aqueous HMB solution containing a monovalent cation-containing compound and having a pH of 4.0 to 10.0, a step of precipitating a crystal of a monovalent cation salt of HMB in the aqueous solution, and a step of collecting the crystal of a monovalent cation salt of HMB from the aqueous solution, wherein the monovalent cation-containing compound is a sodium-containing compound, a potassium-containing compound, or an ammonium-containing compound.
16. The process according to claim 15 , wherein the step of precipitating a monovalent cation salt of HMB is a step of adding or adding dropwise a solvent selected from the group consisting of nitrile and ketone to precipitate a crystal of a monovalent cation salt of HMB.
17. The process according to claim 16 , wherein the nitrile is acetonitrile and the ketone is a solvent selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone and diethyl ketone.
18. The process according to claim 11 , wherein the monovalent cation-containing compound is a sodium-containing compound.
19. The process according to claim 11 , wherein the monovalent cation-containing compound is a potassium-containing compound.
20. The process according to claim 11 , wherein the monovalent cation-containing compound is an ammonium-containing compound.
21. The process according to claim 15 , wherein the monovalent cation-containing compound is a sodium-containing compound.
22. The process according to claim 15 , wherein the monovalent cation-containing compound is a potassium-co taming compound.
23. The process according to claim 15 , wherein the monovalent cation-containing compound is an ammonium-containing compound.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.